Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum ® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President and Chief Executive Officer, effective August 1, 2026.

As part of the leadership transition, Mr. Sébastien Plouffe, Founder and Chief Executive Officer, will now assume the position of Executive Chairman of the Board, where he will continue to play a critical leadership role in guiding the Company's strategic direction, financing initiatives, corporate partnerships, and long-term growth.

Since joining Defence in 2025, Dr. Phinney has played a key role in supporting Defence's strategic evolution, strengthening its scientific and commercial positioning, and advancing the Accum ® technology into the next-generation intracellular drug delivery platform. She joined Defence as Strategy & Business Advisor in July 2025 and was appointed to the Board of Directors in September 2025.

Dr. Phinney mentioned "I am honoured to be taking on the leadership of Defence Therapeutics at this exciting period of growth for the Company. Defence has built a differentiated technology platform with the potential to transform the delivery of complex biologics and targeted therapeutics. I look forward to working alongside our outstanding scientific team, Board of Directors, partners, and shareholders to accelerate the development of our pipeline, expand the applications of the Accum ® platform, and position Defence as a global leader in precision intracellular drug delivery."

Dr. Phinney brings more than two decades of international leadership experience spanning pharmaceutical research and development, biotechnology company creation, corporate strategy, business development, and commercialization. She previously held a range of scientific and strategic roles at Abbott and AbbVie (Chicago, USA), supporting strategic planning, alliance management, and business operations across multiple global R&D organizations. She subsequently served as Chief Scientific Officer of Lakeside Discovery, a venture-backed biotechnology company spun-out from Northwestern University in Chicago, advancing academic innovations into therapeutic programs. Most recently, she was the Senior Director of Partnerships and Business Development at adMare BioInnovations, where she helped launch and grow biotechnology companies emerging from Canadian research institutions. She is also the co-founder of Block Biosciences and served as its inaugural Chief Executive Officer, leading the academic biotechnology spinout in the development of first-in-class oncology therapeutics.

Dr. Phinney holds a PhD in Biomedical Research from the University of Basel (Switzerland) and an MBA from Lake Forest Graduate School of Management (Chicago, USA). She has also completed executive education in corporate governance (Rotman School of Management, University of Toronto), private capital investment (Ivey Academy, Western University), high-performance negotiation (Kellogg School of Management, Northwestern University), and business leadership (Kenan-Flagler Business Schoo...